Evidence map›Paper›PMID 36198724›Full record

ArticleScientific reports2022

Influence of Huangqin Decoction on the immune function and fecal microbiome of chicks after experimental infection with Escherichia coli O78.

Junyan Wang, Rui Li, Minai Zhang, Chensheng Gu, Haili Wang, Jianjian Feng, Linjie Bao, Yihe Wu, Shuming Chen, Xichun Zhang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Nutrients · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Junyan Wang *College of Veterinary Medicine, Shanxi Agricultural University, Taigu, People's Republic of China.
Rui Li *College of Pharmaceutical & Food Engineering, Shanxi University of Chinese Medicine, Yuci, People's Republic of China.
Minai Zhang *Technical Center of Taiyuan Customs, Taiyuan, Shanxi, People's Republic of China.
Chensheng GuCollege of Pharmaceutical & Food Engineering, Shanxi University of Chinese Medicine, Yuci, People's Republic of China.
Haili WangCollege of Pharmaceutical & Food Engineering, Shanxi University of Chinese Medicine, Yuci, People's Republic of China.
Jianjian FengCollege of Veterinary Medicine, Shanxi Agricultural University, Taigu, People's Republic of China.
Linjie BaoCollege of Veterinary Medicine, Shanxi Agricultural University, Taigu, People's Republic of China.
Yihe WuCollege of Veterinary Medicine, Shanxi Agricultural University, Taigu, People's Republic of China.
Shuming ChenCollege of Veterinary Medicine, Shanxi Agricultural University, Taigu, People's Republic of China. 13834834183@163.com.
Xichun ZhangCollege of Pharmaceutical & Food Engineering, Shanxi University of Chinese Medicine, Yuci, People's Republic of China. zxcxpy@126.com.
Shanxi Agricultural University · CNShanxi University · CNTaiyuan Heavy Industry (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huangqin Decoction (HQD), a traditional Chinese medicine formula from the Shang Han Lun written by Zhang Zhongjing, has been used in China for nearly two thousand years. According to the traditional Chinese medicine and previous literature, HQD has the effect of clearing heat, removing toxins, relieving diarrhea and pain. Therefore, HQD was used to prevent or cure many diseases, such as inflammation, diarrhea, malaria, and other acute or chronic gastrointestinal diseases. The effect of HQD, one-herb-absent HQD treatments and enrofloxacin (ENR) on the average daily gain (ADG), mortality rates, visceral index and toll-like receptors (TLRs), inflammatory factors and intestinal microflora in E. coli O78-inoculated chicks were investigated. HQD supplementation increased ADG and reduced the mortality rates caused by E. coli challenge, decreased the heart, liver, bursa of Fabricius (BF) and spleen index. HQD supplementation decreased the serum lysozyme (LZM), IL-1β, TNF-α, IL-10, IL-6 level, down-regulated the mRNA expression of TLR4, -5 and -15 in the spleen by E. coli challenged chicks, and up-regulated the mRNA expression of TLR4, -5 and -15 in BF. At the phylum level, HQD supplementation reversed the increase of Operational Taxonomic Unit (OTUs), decreased the relative abundance of harmful bacteria Proteobacteria, increased the relative abundance of probiotic bacteria Bacteroidetes and Firmicutes. At the genus level, HQD decreased the relative abundance of harmful bacteria Escherichia-Shigella and Pseudomonas. It means that HQD treatment reversed the change of the gut microbiota structure. Compared with HQD, HQD-DZ and HQD-HQ increased the mortality rates. HQD-HQ decreased the ADG and liver index. HQD-GC decreased the spleen index. All herb-absent increased the serum IL-6, but only the HQD-HQ and HQD-SY increased the serum TNF-α. All herb-absent did not activate the TLRs signaling pathways in spleen and BF of chicks. The harmful bacteria Escherichia-Shigella were increased in HQD-HQ and HQD-DZ treatments. HQD-DZ treatment also increased the level of Proteobacteria. The results showed that dietary supplementation with HQD, by down-regulating the mRNA expression of TLR4, -5 and -15 in the spleen, further decreasing the serum LZM and IL-1β, TNF-α, IL-10, IL-6 level, improves the immune function and reverses the change of fecal microbiome in chicks challenged with E. coli. In herb-absent supplementation, the results showed that SY and DZ play a key role in reducing the levels of inflammatory factors and keeping fecal microbiome balance respectively. More importantly, HQ is indispensable in HQD, not only play a key role in reducing the level of inflammatory factors, but also in keeping the balance of fecal microflora.

Indexed as

Gastrointestinal MicrobiomeScutellaria baicalensisAnimalsChickensDiarrheaEnrofloxacinEscherichia coliImmunityInterleukin-10Interleukin-6MuramidaseRNA, MessengerToll-Like Receptor 4Tumor Necrosis Factor-alphaEnrofloxacinInterleukin-10Interleukin-6MuramidaseRNA, MessengerToll-Like Receptor 4Tumor Necrosis Factor-alpha

Identifiers

PMID36198724
PMCPMC9534884
OpenAlexW4302008103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.